

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2022 October 15; 14(10): 1892-2087



**MINIREVIEWS**

- 1892 Go-Ichi-Ni-San 2: A potential biomarker and therapeutic target in human cancers  
*Shan DD, Zheng QX, Chen Z*
- 1903 Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis  
*Zhang HQ, Li J, Tan CL, Chen YH, Zheng ZJ, Liu XB*

**ORIGINAL ARTICLE****Basic Study**

- 1918 Transcriptional factor III A promotes colorectal cancer progression by upregulating cystatin A  
*Wang J, Tan Y, Jia QY, Tang FQ*
- 1933 VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors  
*Wang MQ, Li YP, Xu M, Tian Y, Wu Y, Zhang X, Shi JJ, Dang SS, Jia XL*
- 1949 Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer  
*Feng ML, Wu C, Zhang HJ, Zhou H, Jiao TW, Liu MY, Sun MJ*
- 1968 Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells  
*Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX*
- 1981 Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma  
*Huang EM, Ma N, Ma T, Zhou JY, Yang WS, Liu CX, Hou ZH, Chen S, Zong Z, Zeng B, Li YR, Zhou TC*

**Retrospective Study**

- 2004 Multi-slice spiral computed tomography in differential diagnosis of gastric stromal tumors and benign gastric polyps, and gastric stromal tumor risk stratification assessment  
*Li XL, Han PF, Wang W, Shao LW, Wang YW*
- 2014 Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy  
*Zhao JY, Tang QQ, Luo YT, Wang SM, Zhu XR, Wang XY*

**Observational Study**

- 2025 Role of sex on psychological distress, quality of life, and coping of patients with advanced colorectal and non-colorectal cancer  
*Pacheco-Barcia V, Gomez D, Obispo B, Mihic Gongora L, Hernandez San Gil R, Cruz-Castellanos P, Gil-Raga M, Villalba V, Ghanem I, Jimenez-Fonseca P, Calderon C*

- 2038** Droplet digital polymerase chain reaction assay for methylated ring finger protein 180 in gastric cancer

*Guo GH, Xie YB, Jiang T, An Y*

**Prospective Study**

- 2048** Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study

*Chen N, Li CL, Peng YF, Yao YF*

**META-ANALYSIS**

- 2061** Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis

*Bai XS, Zhou SN, Jin YQ, He XD*

**CASE REPORT**

- 2077** Disseminated carcinomatosis of the bone marrow caused by granulocyte colony-stimulating factor: A case report and review of literature

*Fujita K, Okubo A, Nakamura T, Takeuchi N*

**CORRECTION**

- 2085** Correction to "Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 $\alpha$ -induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis"

*Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ*

**ABOUT COVER**

Editorial Board of *World Journal of Gastrointestinal Oncology*, Sezer Saglam, MD, Full Professor, Medical Oncology, Demiroglu Bilim University, Istanbul 34349, Turkey. [saglam@istanbul.edu.tr](mailto:saglam@istanbul.edu.tr)

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (*WJGO*, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJGO* mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

**INDEXING/ABSTRACTING**

The *WJGO* is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJGO* as 3.404; IF without journal self cites: 3.357; 5-year IF: 3.250; Journal Citation Indicator: 0.53; Ranking: 162 among 245 journals in oncology; Quartile category: Q3; Ranking: 59 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The *WJGO*'s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Gastroenterology is 72/149; Oncology is 203/360.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

October 15, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Basic Study

## Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer

Ming-Liang Feng, Can Wu, Hui-Jing Zhang, Huan Zhou, Tai-Wei Jiao, Meng-Yuan Liu, Ming-Jun Sun

**Specialty type:** Oncology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C, C

Grade D (Fair): D

Grade E (Poor): E

**P-Reviewer:** Imai Y, Japan; Jeong KY, South Korea; Linnebacher M, Germany; Naserian S, France

**Received:** May 19, 2022

**Peer-review started:** May 19, 2022

**First decision:** June 6, 2022

**Revised:** June 20, 2022

**Accepted:** September 21, 2022

**Article in press:** September 21, 2022

**Published online:** October 15, 2022



**Ming-Liang Feng, Can Wu, Hui-Jing Zhang, Huan Zhou, Tai-Wei Jiao, Meng-Yuan Liu, Ming-Jun Sun**, Department of Endoscopy, The First Hospital Affiliated to China Medical University, Shenyang 110001, Liaoning Province, China

**Corresponding author:** Ming-Jun Sun, Doctor, PhD, Chief Physician, Professor, Department of Endoscopy, The First Hospital Affiliated to China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. [sunydyy@163.com](mailto:sunydyy@163.com)

### Abstract

#### BACKGROUND

The androgen responsive gene, ELL-associated factor 2 (EAF2), expressed in benign prostate tissues, has been shown to play an important role in tumor suppression in a variety of malignant tumors. In addition, some scholars found that EAF2 frameshift mutations are associated with intratumor heterogeneity in colorectal cancer (CRC) and inactivation of EAF2 in microsatellite instability-high CRC. However, the molecular mechanism by which EAF2 is involved in CRC invasion and metastasis remains unclear.

#### AIM

To determine the clinical value of expression of EAF2 protein in CRC, and to study the effects of EAF2 on the invasion, migration, and angiogenesis of CRC cells *in vitro*.

#### METHODS

In this study, we collected colorectal adenocarcinoma and corresponding adjacent tissues to investigate the clinical expression of EAF2 protein in patients with advanced CRC. Subsequently, we investigated the effect of EAF2 on the invasion, migration, and angiogenesis of CRC cells *in vitro* using plasmid transfection.

#### RESULTS

EAF2 protein was lowly expressed in cancer tissues of patients with advanced CRC. Kaplan-Meier survival analysis showed that the survival rate of the high EAF2 level group was higher than that of the low EAF2 level group.

#### CONCLUSION

Our results demonstrated that EAF2, as a tumor suppressor, may inhibit the invasion, metastasis, and angiogenesis of CRC cells by regulating the signal transducer and activator of transcription 3/transforming growth factor- $\beta$ 1

crosstalk pathway, and play a cancer suppressive and protective role in the occurrence and development of CRC. Our findings are of great significance to provide a new idea and theoretical basis for the targeted diagnosis and treatment of CRC.

**Key Words:** ELL-associated factor 2; Transforming growth factor- $\beta$ 1; Signal transducer and activator of transcription 3; Colorectal cancer; Invasion; Migration; Angiogenesis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Androgen-responsive gene ELL-associated factor 2 (EAF2) plays an important role in tumor suppression in a variety of malignant tumors. We found that EAF2 protein was lowly expressed in colorectal cancer (CRC) tissues. Kaplan-Meier survival analysis showed that the survival rate of the group with high EAF2 level was higher than that of the group with low EAF2 level. Moreover, EAF2 may play a tumor suppressive and protective role in CRC by inhibiting the invasion, metastasis, and angiogenesis *via* regulating the signal transducer and activator of transcription 3/transforming growth factor beta 1 crosstalk pathway. Our findings are of great significance to provide a new idea and theoretical basis for targeting diagnosis and therapy of CRC.

**Citation:** Feng ML, Wu C, Zhang HJ, Zhou H, Jiao TW, Liu MY, Sun MJ. Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer. *World J Gastrointest Oncol* 2022; 14(10): 1949-1967

**URL:** <https://www.wjgnet.com/1948-5204/full/v14/i10/1949.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v14.i10.1949>

## INTRODUCTION

Colorectal cancer (CRC) is one of the tumors with high morbidity and mortality in the world. The Global Cancer Statistics 2020 revealed that CRC was estimated to be the third most diagnosed malignant tumor (10%) and the second leading cause of cancer death (9.4%) worldwide[1]. As an important process in the development of CRC, tumor metastasis is a key factor affecting the survival rate of CRC patients. Approximately 35% of newly diagnosed CRC patients present metastatic disease, and about 50% of patients with non-metastatic disease eventually develop metastatic disease[2]. Most regrettably, the 5-year survival rate of patients with metastatic CRC is less than 10%[3]. There is a great need to elucidate the molecular mechanism of CRC invasion and metastasis, which is beneficial to explore new potential molecular markers and the direction of targeted therapy of CRC.

ELL-associated factor 2 (EAF2) was first identified as an androgen-responsive gene expressed by luminal epithelial cells in benign prostatic tissue[4,5]. Interestingly, EAF2 has been found to inhibit cell proliferation and tumor size in prostate cancer *in vivo*[6], and corresponding to that, knockdown of EAF2 in prostate cancer cells resulted in increased proliferation and migration[7]. In recent years, more and more studies have shown that EAF2 plays an important role in tumor suppression in a variety of malignant tumors[8]. Furthermore, scholars have identified intratumor heterogeneity (ITH) of EAF2 frameshift mutations in CRC and the inactivation of EAF2 in microsatellite instability (MSI)-high CRC [9]. This finding suggests that EAF2 inactivation may occur during tumor progression rather than tumorigenesis. Besides, EAF2 gene silencing could modulate the cytotoxic response of colon cancer cell line HCT116 to statins[10]. However, studies on the expression and role of EAF2 protein in CRC are still lacking. The molecular mechanism of involvement of EAF2 in CRC invasion and metastasis remains unclear.

EAF2 has been shown to attenuate transforming growth factor beta 1 (TGF- $\beta$ 1)-induced G1 cell cycle arrest and cell migration in a variety of tumor cells, such as renal carcinoma cells, human hepatocellular carcinoma cells, and breast cancer cells[11]. It is worth noting that blocking the TGF- $\beta$ 1 signaling pathway may be a therapeutic strategy for attenuating tumor metastasis in CRC metastatic models[12]. In addition, the signal transducer and activator of transcription 3 (STAT3) pathway is involved in the process of TGF- $\beta$ 1-induced epithelial-mesenchymal transition (EMT), and cell migration and invasion in malignant tumor[13,14]. As well, EAF2 knockout induced STAT3 phosphorylation (Tyr705) in prostate cancer cells, which drove tumor progression in prostate cancer[15]. Therefore, in this study, we investigated the effect of EAF2 on the STAT3/TGF- $\beta$ 1 pathway in CRC cells to explore the possible mechanism of action of EAF2 in CRC.

All tissues in the body need blood vessels to provide nutrients and oxygen to maintain growth and function[16], so angiogenesis provides necessary functions in normal growth and biological development processes, such as embryonic development, bone formation, and the function of ovaries

and other endocrine glands[17]. Not only that, tumor growth and metastasis also require angiogenesis [18]. Abnormalities in vasculogenesis and spermatogenesis have been found in EAF2 knockout mice [19]. Besides, EAF2 negatively regulated the activity of angiogenic factor hypoxia inducible factor (HIF)-1 $\alpha$ [20]. Therefore, exploring the regulatory role of EAF2 in CRC angiogenesis may provide a theoretical basis for anti-angiogenic treatment. Activation of the JAK2/STAT3 (Tyr705) signaling pathway in CRC cells promoted cell proliferation and angiogenesis by positively regulating HIF-1 $\alpha$ /vascular endothelial growth factor A (VEGFA)[21,22]. Meanwhile, HIF-1 $\alpha$  sumoylation may elevate the microvascular density and lumen size and promote tumor growth by amplifying TGF- $\beta$ /Smad signaling in tumor cells [23,24]. Therefore, we further investigated the role of EAF2 in CRC angiogenesis *via* the STAT3/TGF- $\beta$ 1 pathway.

In this study, we aimed to determine the clinical value of expression of EAF2 protein in CRC. Furthermore, we studied the effects of EAF2 on the invasion, migration, and angiogenesis of CRC cells *in vitro*. In addition, we preliminarily explored the mechanism by which EAF2 affects the biological function and angiogenesis of CRC cells *via* regulating the STAT3/TGF- $\beta$ 1 pathway. Our findings are of great significance to provide a new idea and theoretical basis for the targeted diagnosis and therapy of CRC.

## MATERIALS AND METHODS

### CRC patients and tissue samples

We selected 70 cases of advanced CRC from the First Affiliated Hospital of China Medical University (Liaoning, China) between 2012 and 2015. This study was approved by the Institutional Review Board of the First Affiliated Hospital of China Medical University (Registration No. 2021-68-2; informed consent was waived). Seventy pairs of histological sections of colorectal adenocarcinomas and corresponding paracancerous tissue that had been surgically removed were studied. In addition, another eight pairs of fresh cancer and adjacent tissue were selected for western blot assay. None of patients received radiotherapy or chemotherapy prior to surgical resection. We defined tumor stages according to the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system (8<sup>th</sup> Edition).

### Reagents

Recombinant human TGF- $\beta$ 1 (mammalian derived) was bought from PeproTech (100-21) (United States). The antibodies used in this study include: Rabbit monoclonal anti-EAF2 (ab237753) (for IHC-P), rabbit monoclonal anti-EAF2 [EPR7117(2)] (ab151692) (for western blot) (Abcam, United Kingdom); rabbit monoclonal anti-TGF- $\beta$ 1 (56E4) (#3709), rabbit monoclonal anti-phospho-STAT3 (Tyr705) (#9145), rabbit monoclonal anti-STAT3 (#30835) (Cell Signaling, Danvers, MA, United States); rabbit polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (FL-335) (Santa Cruz, CA, United States).

### Cell culture

CRC cell lines (SW480, RKO, HCT116, HT29, and HIEC) and the human normal colon cell line NCM460 were purchased from the Cell Bank of the Chinese Academy of Science (Shanghai, China). And these cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, United States) containing 10% fetal bovine serum (FBS) (Gibco) at 37 °C with 5% CO<sub>2</sub> in a humidified incubator. Human umbilical vein endothelial cells (HUVECs) were also purchased from the Cell Bank of the Chinese Academy of Science (Shanghai, China) and cultured in DMEM medium (Gibco) containing 10% FBS at 37 °C with 5% CO<sub>2</sub> in a humidified incubator.

### Cell transfection

The plasmid for overexpressing human EAF2 (GenBank No. NM\_018456) was designed and synthesized by GeneChem (Shanghai, China). And three plasmid targets for silencing human STAT3 (GenBank No. NM\_139276) were also provided by GeneChem. The sequences are listed in Table 1. The cell transfection was performed using the Lipofectamine 2000 Kit (Invitrogen, Carlsbad, CA, United States). Cells were plated into six-well plates and transfected with 4.0  $\mu$ g plasmid DNA. Six hours after transfection, cells were treated with medium containing 10% FBS.

### Immunohistochemistry

Typical CRC tissues and corresponding paracancer tissues were selected. The sections were dewaxed, rehydrated, and heated using a pressure-cooker for antigen retrieval. And then antigenic repair was performed with citric acid. Subsequently, the sections were incubated overnight at 4 °C with rabbit monoclonal anti-EAF2 antibody (1:200 dilution, ab237753), followed by incubation with the secondary antibody for 40 min at 37 °C. Finally, the slides were stained with diaminobenzidine, counter-stained with hematoxylin, air-dried, dehydrated, and mounted.

**Table 1** Gene sequences used for transfection

Gene	Sequences
STAT3-siRNA	1-siRNA 5'-CCGGGCTGACCAACAATCCCAAGAAGCTCGAGTTCTTGGGATTGTGGTCAGCTTTT G-3'
	Anti-sense 5'-AATTCAAAAAGCTGACCAACAATCCCAAGAAGCTCGAGTTCTTGGGATTGTGGTCAGC-3'
2-siRNA	5'-CCGGGCACAATCTACGAAGAATCAACTCGAGTTGATTCTTCGTAGATTGTGCTTTTIG-3'
	Anti-sense 5'-AATTCAAAAAGCACAATCTACGAAGAATCAACTCGAGTTGATTCTTCGTAGATTGTGC-3'
3-siRNA	5'-CCGGGCTGAAATCATCATGGGCTATCTCGAGATAGCCCATGATGATTTCAGCTTTTIG-3'
	Anti-sense 5'-AATTCAAAAAGCTGAAATCATCATGGGCTATCTCGAGATAGCCCATGATGATTTCAGC-3'

STAT3: Signal transducer and activator of transcription 3.

Double blind reading was performed by two experienced pathologists. We calculated the final staining score by multiplying the positive expression score by the intensity score. Five high-power fields (magnification at 200  $\times$ ) were observed on each section. We divided the immunostaining intensity into four categories: 0 (negative immunostaining), 1 (weak immunostaining), 2 (moderate immunostaining), and 3 (strong immunostaining). And the proportion of positive cells scored from 0 to 4 as follows: (1) 0 (positive cells < 5%); (2) 1 (positive cells 5% to 25%); (3) 2 (positive cells 26% to 50%); (4) 3 (positive cells 51% to 75%); and (5) 4 (positive cells > 75%).

### Western blot assay

The tissues and cells were lysed in RIPA lysis buffer containing protease inhibitors such as phenyl-methylsulfonyl fluoride. Protein concentrations were measured with a BCA kit (Beyotime Institute of Biotechnology, China). Equal amounts of protein (50  $\mu$ g per sample) were separated by 10% sodium dodecyl sulfate/polyacrylamide gel electrophoresis and then transferred onto polyvinylidene difluoride membranes at a 200 mA constant current. Primary antibodies for EAF2 (ab151692), TGF- $\beta$ 1, phospho-STAT3 (Tyr705), STAT3, and GAPDH were used at a dilution ratio of 1:1000. Then, anti-rabbit immunoglobulin G secondary antibody (1:5000) was used to incubate the membranes at 37  $^{\circ}$ C for 2 h. The immunoreactive bands were detected with ECL-Plus chemiluminescent detection reagents (Beyotime Institute of Biotechnology) and using the Microchemi 4.2 Bio-imaging system. The expression of proteins of interest was normalized to that of GAPDH. Experiments were repeated at least three times under the same experimental conditions.

### Transwell invasion and migration assays

Before invasion assay, Matrigel (BD Biosciences, San Diego, CA, United States) diluted at a ratio of 1:8 with serum-free medium was used to block the membranes at 37  $^{\circ}$ C for 6 h. A total of  $4 \times 10^4$  cells/well in 200  $\mu$ L serum-free medium were seeded in the upper chambers of 8- $\mu$ m pore transwell plates (3422; Corning Incorporated, NY, United States), and 600  $\mu$ L medium containing 20% FBS was added to the lower chambers. For migration assay,  $2 \times 10^5$  cells/well were seeded into the upper chambers of 8- $\mu$ m pore transwell plates (3422) in 200  $\mu$ L serum-free medium. The lower chambers were filled with 600  $\mu$ L medium with 10% FBS.

After incubation for 72h, the non-invaded or non-migrated cells on the inner surface of the filter membrane were removed by scrubbing with a cotton swab, and the invaded or migrated cells were fixed by methanol. Next, the cells were stained with 0.1% crystal violet. The membranes were moved from the chambers and fixed on cover slides. Invading or metastasizing cells were counted from five random fields under a light microscope (magnification at 200  $\times$ ). The experiments were repeated at least three times under the same experimental conditions.

### Wound healing assay

A total of  $2 \times 10^5$  cells/well were seeded into 6-well plates. Scratch wounds were generated using a 200  $\mu$ L pipette tip when the cells reached 90% confluence. Afterwards, the cells were washed with phosphate buffered saline (PBS) three times, and then incubated in medium containing 2% serum. The scratch wounds were photographed at 0 h, 6 h, 12 h, 24 h, 48 h, and 72 h in five selected regions. ImageJ software (Version 1.46r) was used to measure the wound area (magnification at 40  $\times$ ). The experiments were repeated at least three times under the same experimental conditions.

### Tube formation assay

Before tube formation assay, Matrigel was placed in a 96-well plate at 37  $^{\circ}$ C for 1 h. And the conditioned medium from treated RKO cells was collected and centrifuged at 2000 rpm for 10 min to remove debris. HUVECs at  $1.0 \times 10^4$  cells/well were seeded in a Matrigel coated 96-well plate and cultured in

conditioned medium. After 6 h, capillary morphogenesis was evaluated by inverted microscopy (magnification at 100  $\times$ ). Then, we analyzed the images for evaluating the branch points by means of the angiogenesis analyzer that was developed for the Image J software (Version 1.46r).

#### **HUVEC transwell migration assay**

For HUVEC migration assay,  $1 \times 10^5$  HUVECs were plated in the upper chambers of 8- $\mu$ m pore transwell plates (3422) with 200  $\mu$ L serum-free medium; 600  $\mu$ L conditioned medium was placed in the lower chambers. After 6 h, the cells were fixed with methanol and non-migrated cells were removed from the inner surface of the filter membrane. The cells on the lower surface of the membrane were stained with 0.1% crystal violet, and the number of migrated cells was counted from five fields (magnification at 200  $\times$ ) under an optical microscope. The experiments were repeated at least three times under the same experimental conditions.

#### **HUVEC scratch assay**

For scratch assay,  $2 \times 10^5$  HUVECs/well were seeded in 6-well plate. When cells reached about 90% confluence, a 200  $\mu$ L tip was used to scratch the cells. The cells were then washed with PBS three times and incubated with 2 mL conditioned medium per well. The scratch was photographed at 0 h, 12 h, and 24 h time points under a microscope in five selected regions (magnification at 40  $\times$ ). ImageJ software (Version 1.46r) was used to measure the wound area. Experiments were repeated at least three times under the same experimental conditions.

#### **Statistical analysis**

The results in this study were analyzed with SPSS software (Version 26). Pearson's chi-squared test was adopted to evaluate the correlation between EAF2 protein and clinicopathological parameters. The expression differences of EAF2 between paired adenocarcinoma and paracancerous tissues were analyzed by Wilcoxon sign rank test. Receiver operating characteristic (ROC) curve was used to determine the Youden index to delimit the high and low expression of EAF2 in tissues. The data are shown as the mean  $\pm$  SD. Student's *t* test was used for analyzing the differences between two groups, while for differences among three or more groups, one-way ANOVA was performed. The Kaplan-Meier method was used to estimate the cumulative survival of patients, and the Log-rank test was used to test the significance of the differences in survival. Cox proportional hazards regression model was used for multivariate analysis to evaluate the independent prognostic effect of EAF2 protein on survival. All the statistics were subjected to ANOVA followed by Bonferroni test. Two-sided *P* values < 0.05 were considered statistically significant.

## **RESULTS**

### **EAF2 protein expression is decreased in advanced CRC tissue**

To assess the expression and localization of EAF2 protein in CRC specimens, we examined the expression of EAF2 at the protein level in paired adenocarcinoma and paracancerous tissues by immunohistochemical analysis and western blot assay. Immunohistochemical analysis showed that EAF2 protein was mainly localized in the cytoplasm of colorectal epithelial cells (Figure 1A). The median EAF2 score was 6.0 in tumor tissue and 6.8 in adjacent non-tumor tissue, with a median difference of -2.0. Moreover, Wilcoxon signed-rank test of paired samples showed that EAF2 expression was lower in tumor tissue than in non-tumor tissue ( $Z = -3.727$ ,  $P < 0.001$ ). Additionally, we used western blot assay to measure the level of EAF2 protein expression in eight matched pairs of fresh colorectal adenocarcinoma and corresponding paracancerous tissue. The results also revealed a lower level of EAF2 protein expression ( $P = 0.012$ ) in tumor tissue compared with adjacent non-tumor tissue (Figure 1B). According to the Youden index determined by ROC curve, the cut-off value delimiting high and low expression of EAF2 (dependent variable is non-cancer) was determined to be 6.2 ( $P < 0.001$ ). In this study, we found low EAF2 expression in 58 of 70 CRC tissues.

We then assessed the relationship between EAF2 protein expression and major clinicopathological characteristics. Statistical results showed that the expression of EAF2 protein in CRC tissue was negatively correlated with distant metastasis ( $r = -0.268$ ,  $P = 0.025$ ) and carcinoembryonic antigen (CEA) ( $r = -0.249$ ,  $P = 0.038$ ), but not with other clinical characteristics, such as age, sex, primary tumor site, tumor size, tumor histological differentiation, degree of differentiation, vasculolymphatic and/or perineural invasion, tumor stage, tumor invasion depth, lymph node status, carbohydrate antigen 19-9 (CA19-9), P53, or CDX2 (Table 2). High expression of CEA, CA19-9, P53, and CDX2 was defined as a score of  $\geq 3$ , and their low expression was defined as a score of  $< 3$ .

### **Survival analysis of EAF2 expression in patients with advanced CRC**


Kaplan-Meier survival analysis and Log-rank testing for overall survival (OS) showed that the survival rate of the group with high EAF2 level was higher than that of the group with low EAF2 level ( $P =$

**Table 2** Baseline characteristics of patients with advanced colorectal cancer and their correlation with immunohistochemical expression of ELL-associated factor 2

Clinicopathologic characteristic	Cases, n (%)	EAF2		P value
		Low (n = 58)	High (n = 12)	
Age (yr)				0.831
< 61 (median)	47.14	27	6	
$\geq$ 61	52.86	31	6	
Gender				0.589
Male	57.14	34	6	
Female	42.86	24	6	
Tumor site				0.162
Colon	34.29	22	2	
Rectum	65.71	36	10	
Size of the tumor (cm)				0.726
$\leq$ 4	37.14	21	5	
> 4	62.86	37	7	
Histological type				0.210
Mucinous	20.00	10	4	
Non-mucinous	80.00	48	8	
Degree of differentiation				0.318
Well/moderate	62.86	38	6	
Poor/mucinous	37.14	20	6	
Angiolymphatic and/or perineural invasion				0.113
Absent	45.71	24	8	
Present	54.29	34	4	
Tumor stage (TNM)				0.240
I-II	42.86	23	7	
III-IV	57.14	35	5	
Tumor invasion depth				0.682
T2-T3	52.86	30	7	
T4	47.14	28	5	
Lymph node status				0.210
N0	50.00	27	8	
N1-N2	50.00	31	4	
Distant metastasis				0.025
Absent	74.29	40	12	
Present	25.71	18	0	
CEA				0.038
Normal	65.71	35	11	
High	34.29	23	1	
CA19-9				0.445
Normal	40.00	22	6	
High	60.00	36	6	


P53					0.589
Normal	42.86	24	6		
High	57.14	34	6		
CDX2					0.350
Normal	22.86	12	4		
High	77.14	46	8		

EAF2: ELL-associated factor 2; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.



**Figure 1** ELL-associated factor 2 protein is decreased in colorectal cancer tissue. A: Representative immunohistochemical staining for ELL-associated factor 2 (EAF2) in colorectal adenocarcinoma tissue and adjacent tissue (magnification, 200  $\times$  and 400  $\times$ ); B: western blot showing lower EAF2 level in colorectal adenocarcinoma fresh tissue than in corresponding para-cancerous tissue (T, colorectal adenocarcinoma tissue; N, adjacent non-tumor tissue). EAF2: ELL-associated factor 2; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

0.026). **Figure 2** shows the Kaplan-Meier survival curves of advanced CRC patients with high and low EAF2 expression. We used Cox proportional-hazards model to evaluate the effect of EAF2 protein on OS in patients with advanced CRC. From univariate analysis, we found that angiolymphatic and/or perineural invasion ( $P = 0.003$ ), tumor stage ( $P = 0.012$ ), tumor invasion depth ( $P = 0.011$ ), lymph node



**Figure 2** Kaplan-Meier survival curves for ELL-associated factor 2 expression in colorectal cancer tissue. The survival rate of the group with high ELL-associated factor 2 (EAF2) levels was higher than that of the group with low EAF2 levels. EAF2: ELL-associated factor 2.

status ( $P = 0.017$ ), distant metastasis ( $P < 0.001$ ), and EAF2 protein expression level ( $P = 0.038$ ) were significantly correlated with OS (Table 3). The clinicopathological characteristics with  $P < 0.3$  in univariate analysis were included in multivariate analysis, and the independent prognostic effect of EAF2 protein on OS was assessed by adjusting for confounding factors. However, multivariate analysis proved that tumor invasion depth ( $P = 0.035$ ) and distal metastasis ( $P < 0.001$ ) were independent prognostic factors for OS (Table 3).

#### Overexpression of EAF2 inhibits invasion and migration of CRC cells

We cultured CRC cells *in vitro* to determine the expression of EAF2 protein and further investigate its effects on the biological function of CRC cells. The expression level of EAF2 protein in human CRC cell lines (SW480, RKO, HCT116, HT29, and HIEC) were observably lower than that in normal colorectal epithelial cells (NCM460) (Figure 3). There was a considerable decrease (64.11%) in EAF2 protein expression in colon cancer RKO cells ( $P < 0.001$ ) (Figure 3). Thus, we used RKO cells in subsequent experiments.

Subsequently, we overexpressed EAF2 protein by plasmid transfection technique to investigate the effects of EAF2 overexpression on the invasion and migration of RKO cells. EAF2 overexpression significantly increased the protein expression level in RKO cells, which was 2.25-fold higher than that of the control group (Figure 4A,  $P < 0.001$ ). Results of transwell invasion assay showed that EAF2 overexpression significantly weakened the invasion ability of RKO cells (Figure 4B,  $P < 0.001$ ). Analogously, cells transfected with EAF2-overexpressing plasmid also showed a poorer migration capacity than the control group in the transwell migration assay (Figure 4B,  $P < 0.001$ ). In addition, as shown in Figure 4C, EAF2 overexpression reduced the wound healing ability of RKO cells ( $P < 0.001$ ).

#### Overexpression of EAF2 suppresses the activity of STAT3/TGF- $\beta$ 1 crosstalk pathway

In this study, we set out to investigate the molecular mechanism of EAF2 on RKO cells *in vitro*. Phosphorylated STAT3 (Tyr705) and TGF- $\beta$ 1 protein expression levels were significantly increased in human CRC cell lines (SW480, RKO, HCT116, HT29, and HIEC) compared with normal colorectal epithelial cells (NCM460) (Figure 3). The upregulation of phosphorylated STAT3 protein (Tyr705) (with a 1.585-fold increase,  $P < 0.001$ ) and TGF- $\beta$ 1 protein (with a 2.485-fold increase,  $P < 0.001$ ) in RKO cells was statistically significant.


Compared with control cells, TGF- $\beta$ 1 protein expression level was significantly decreased in RKO cells transfected with EAF2-overexpressing plasmid (Figure 5A). Meanwhile, we also found that overexpression of EAF2 remarkably decreased phosphorylated STAT3 (Tyr705) levels in RKO cells, but not total STAT3 levels (Figure 5A).

And then we knocked down STAT3 gene by transfecting with STAT3 siRNA (Figure 6A). We found that inhibition of STAT3 phosphorylation (with a reduction of 60.25%,  $P < 0.001$ ) resulted in a significant decrease in TGF- $\beta$ 1 protein expression ( $P < 0.001$ ) in RKO cells but not in EAF2 ( $P = 0.228$ ) (Figure 6B). Furthermore, we treated RKO cells with TGF- $\beta$ 1 recombinant protein to clarify the regulatory effect of TGF- $\beta$ 1 on EAF2 protein expression and STAT3 phosphorylation. The results revealed that TGF- $\beta$ 1 recombinant protein reversed the decrease of phosphorylated STAT3 (Tyr705) induced by EAF2 overexpression ( $P < 0.001$ ) (Figure 5A). However, our results showed that TGF- $\beta$ 1 recombinant protein did not affect the expression of EAF2 protein ( $P = 0.099$ ) in RKO cells (Figure 5A).

**Table 3 Univariate and multivariate survival analyses of overall survival for colorectal cancer by Cox regression**

Variable	Univariate analysis			Multivariate analysis		
	HR	95%CI	P value	HR	95%CI	P value
Age (yr) ( $\geq 61$ / $< 61$ )	1.203	0.633-2.284	0.573			
Gender (female/male)	0.894	0.472-1.695	0.732			
Tumor site (colon/rectum)	1.524	0.791-2.935	0.208	0.682	0.288-1.618	0.386
Size of the tumor, cm ( $> 4$ / $\leq 4$ )	0.929	0.479-1.799	0.827			
Histological type (mucinous/non-mucinous)	1.481	0.619-3.544	0.378			
Degree of differentiation (poor/mucinous, well/moderate)	0.863	0.446-1.670	0.661			
Angiolymphatic and/or perineural invasion (present/absent)	0.342	0.169-0.693	0.003	0.194	0.036-1.042	0.056
Tumor stage (III-IV/I-II)	0.404	0.200-0.816	0.012	4.199	0.603-29.234	0.147
Tumor invasion depth (T4/T2-T3)	0.426	0.221-0.822	0.011	0.253	0.071-0.908	0.035
Lymph node status (N1-N2/N0)	0.447	0.231-0.867	0.017	3.138	0.766-12.863	0.112
Distant metastasis (present/absent)	0.203	0.105-0.393	$< 0.001$	0.149	0.056-0.397	$< 0.001$
EAF2 (low/high)	3.481	1.069-11.341	0.038	2.261	0.653-7.829	0.198
CEA (high/low)	1.092	0.559-2.136	0.796			
CA19-9 (high/low)	0.740	0.378-1.446	0.378			
P53 (high/low)	0.579	0.295-1.134	0.111	0.697	0.336-1.448	0.333
CDX2 (high/low)	0.694	0.305-1.576	0.383			


HR: Hazard ratio; CI: Confidence interval; EAF2: ELL-associated factor 2; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.



**Figure 3 Protein levels of ELL-associated factor 2, phosphorylated-signal transducer and activator of transcription 3, and transforming growth factor- $\beta$ 1 in colorectal cancer cell lines (SW480, RKO, HCT116, HT29, and HIEC) and normal colorectal epithelial cells (NCM460) by western blot assay.** A: Western blot results of proteins in in colorectal cancer cell lines (SW480, RKO, HCT116, HT29, and HIEC) and normal colorectal epithelial cells (NCM460); B: Relative expression of the proteins. The data are shown as the mean  $\pm$  SD. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.001$ . p-STAT3: Phosphorylated-signal transducer and activator of transcription 3; TGF- $\beta$ 1: Transforming growth factor- $\beta$ 1; EAF2: ELL-associated factor 2; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

### Overexpression of EAF2 inhibits invasion and migration of CRC cells by down-regulating the activity of STAT3/TGF- $\beta$ 1 crosstalk pathway

We attempted to further determine whether EAF2 regulates the biological function of CRC cells by regulating the activity of STAT3/TGF- $\beta$ 1 crosstalk pathway. We used TGF- $\beta$ 1 recombinant protein to treat the RKO cells transfected with EAF2-overexpressing plasmid for 24 h. As a result, the invasiveness and metastasis capability of RKO cells weakened by EAF2 overexpression was partially reversed by



**Figure 4** Overexpression of ELL-associated factor 2 inhibits the invasion and migration of RKO cells. A: Protein levels of ELL-associated factor 2 (EAF2) in RKO cells transfected with EAF2 overexpression vector by western blot assay; B: Invasion and migration abilities evaluated by transwell assay; C: Migration ability analyzed by wound healing assay after 72 h; D: Migration and invasion abilities of RKO cells measured using ImageJ software. The data are shown as the mean  $\pm$  SD. <sup>a</sup> $P < 0.001$ ; <sup>b</sup> $P < 0.05$ . RKO-C: The group of RKO control cells; EAF2-OV: The group of RKO cells transfected with ELL-associated factor 2 overexpression vector; EAF2-NC: The group of RKO cells transfected empty vector; EAF2: ELL-associated factor 2; GAPDH: Glyceraldehyde-3-phosphate

dehydrogenase.

TGF- $\beta$ 1 recombinant protein (Figures 5B and 5C).

### **Overexpression of EAF2 inhibits CRC angiogenesis**

In this study, we preliminarily investigated the effects of RKO cells overexpressing EAF2 on the migration and tube formation abilities of HUVECs. First, HUVECs were cultured with DMEM medium containing 10% serum[25]. After 2-6 passages of cells, HUVECs were subcultured into corresponding petri dishes. We then treated HUVECs with conditioned medium from RKO cells transfected with EAF2-overexpressed plasmid (EAF2-OV group) or empty control plasmid (EAF2-NC group) for 24 h. Compared with the control group (RKO-C group), whose conditioned medium was collected from RKO cells cultured with 10% serum for 24 h, the tube formation (Figure 7A) and migration (Figures 7B and 7C) of HUVECs in the EAF2-OV group were significantly reduced, while the differences in the EAF2-NC group were not statistically significant. Our results indicated that overexpression of EAF2 protein may inhibit angiogenesis induced by CRC cells *in vitro*.

### **Overexpression of EAF2 regulates CRC angiogenesis via STAT3/TGF- $\beta$ 1 signaling pathway**


STAT3-related pathway and non-specific angiogenic factor TGF- $\beta$ 1 play a proangiogenic role in tumor angiogenesis. Our study showed that overexpression of EAF2 inhibits the activity of the STAT3/TGF- $\beta$ 1 crosstalk pathway in RKO cells. Hence, we next investigated whether EAF2 inhibits CRC angiogenesis through the STAT3/TGF- $\beta$ 1 signaling pathway. We used TGF- $\beta$ 1 recombinant protein to treat RKO cells transfected with or without EAF2-overexpressing plasmid for 24 h, and collected conditioned medium to culture HUVECs. We aimed to investigate whether TGF- $\beta$ 1-related pathways are involved in the molecular mechanism of EAF2 overexpression regulating angiogenesis in RKO cells *in vitro*. Compared with the RKO-C group, the tube formation (Figure 8A) and migration (Figures 8B and 8C) of HUVECs in the EAF2-OV group were significantly decreased. Interestingly, when HUVECs were cultured with conditioned medium from EAF2-overexpressing RKO cells treated with TGF- $\beta$ 1 recombinant protein, the inhibition of EAF2 overexpression on tube formation (Figure 8A) and migration (Figures 8B and 8C) of HUVECs was reversed. Together, these data confirmed our hypothesis that EAF2 overexpression inhibits CRC angiogenesis by suppressing the activity of the STAT3/TGF- $\beta$ 1 crosstalk pathway *in vitro*.

## **DISCUSSION**

Previous studies have supported the role of EAF2 as a tumor suppressor in multiple human tissues[6]. EAF2 knockout mice developed a higher frequency of B-cell lymphoma, lung adenocarcinoma, hepatocellular carcinoma, and prostatic intraepithelial neoplasia[6]. EAF2 and its homologue EAF1 were originally identified as binding partners of the fusion protein ELL (11-19 lysine-rich leukemia) associated with myeloid leukemia[26,27], stimulating the extension activity of ELL. However, EAF2 mutations produce truncated EAF2 mutants, which may be associated with the pathogenesis of MSI-high cancers[9]. Recently, further studies have found ITH in EAF2 frameshift mutations in CRC and the inactivation of EAF2 in MSI-high CRC[9], suggesting that EAF2 mutations may occur during tumor progression rather than during tumorigenesis. However, the expression, role, and molecular mechanism of EAF2 protein in CRC remain unclear.


This study collected colorectal adenocarcinoma and paired adjacent tissues to investigate the clinical expression of EAF2 protein in patients with advanced CRC. Compared with non-tumor tissue, the results of immunohistochemistry and western blot assay showed that the level of EAF2 protein in CRC tissue was significantly lower. And immunohistochemical results indicated that EAF2 protein was mainly expressed in the cytoplasm. Meanwhile, *in vitro* experiments also confirmed that EAF2 expression level in CRC cells was lower than that in normal colorectal epithelial cells. Further analysis of the correlation between EAF2 expression level and clinicopathological characteristics revealed that EAF2 protein level was negatively correlated with distant metastasis and CEA expression level in CRC tissues. These results suggest that EAF2 protein may be related to the invasion and metastasis of CRC. However, further studies are needed to determine the mechanism of decreased EAF2 protein expression in CRC.

Besides, Kaplan-Meier survival analysis showed that the survival rate of the group with high EAF2 levels was higher than that of the group with low EAF2 levels. Although multivariate analysis did not suggest that EAF2 expression level was an independent survival prognostic marker in patients with advanced CRC, univariate analysis suggested that it was an influential factor of survival and prognosis in patients with advanced CRC. However, more cases and more comprehensive clinical studies are needed to further explore this question.



**Figure 5** Overexpression of ELL-associated factor 2 suppresses the activity of the signal transducer and activator of transcription 3/transforming growth factor-β1 pathway to inhibit the invasion and migration of RKO cells. A: Overexpression of ELL-associated factor 2 (EAF2) inhibited the signal transducer and activator of transcription 3/transforming growth factor-β1 (STAT3/TGF-β1) pathway measured by western blot assay. And TGF-β1

recombinant protein abolished EAF2 overexpression-reduced the phosphorylation (Tyr705) of STAT3 protein; B: Invasion and migration abilities evaluated by transwell assay; C: Migration ability analyzed by wound healing assay after 72 h; D: Migration and invasion abilities of RKO cells measured using ImageJ software. The data are shown as the mean  $\pm$  SD. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.001$ . RKO-C: The group of RKO control cells; EAF2-OV: The group of RKO cells transfected with ELL-associated factor 2 overexpression vector; RKO + T: The group of RKO cells treated with 5 ng/mL transforming growth factor- $\beta$ 1 recombinant protein for 24 h; EAF2-OV + T: The group of RKO cells were transfected with EAF2-OV plasmid for 24 h and then cultured with 5 ng/mL transforming growth factor- $\beta$ 1 recombinant protein for 24 h; p-STAT3: Phosphorylated-signal transducer and activator of transcription 3; TGF- $\beta$ 1: Transforming growth factor- $\beta$ 1; EAF2: ELL-associated factor 2; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.




**Figure 6 Silencing signal transducer and activator of transcription 3 decreases transforming growth factor- $\beta$ 1 protein expression in RKO cells.**

**A:** Protein levels of phosphorylated-signal transducer and activator of transcription 3 (p-STAT3) in RKO cells transfected with STAT3 siRNA plasmid by western blot assay; **B:** Knockdown of STAT3 decreased the levels of transforming growth factor- $\beta$ 1 protein but not ELL-associated factor 2 protein in RKO cells. The data are shown as the mean  $\pm$  SD. <sup>a</sup> $P < 0.01$ . RKO-C: The group of RKO control cells; STAT3-si: The group of RKO cells transfected with signal transducer and activator of transcription 3 siRNA plasmid. STAT3-NC: The group of RKO cells transfected empty vector; p-STAT3: Phosphorylated-signal transducer and activator of transcription 3; TGF- $\beta$ 1: Transforming growth factor- $\beta$ 1; EAF2: ELL-associated factor 2; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

In addition, phospho-STAT3 (Tyr705) and TGF- $\beta$ 1 protein were highly expressed in CRC cells in this study. Studies have shown that TGF- $\beta$ 1 is highly expressed in CRC tissue, and overexpression of TGF- $\beta$ 1 facilitates the invasion and migration of CRC cells *in vitro*[28]. Furthermore, blocking the TGF- $\beta$ 1 signaling pathway in CRC metastatic models may serve as a therapeutic strategy to weaken tumor metastasis *in vivo*[20]. Importantly, STAT3 acts as a positive regulator to activate TGF- $\beta$ 1 to induce tumor EMT and metastasis[14]. Meanwhile, STAT3 is one of the major oncogenic pathways activated in CRC, and its activation can be detected in CRC tissue, primary CRC cells, or CRC cell lines[29-31].

Further studies have revealed that EAF2 attenuates TGF- $\beta$ 1-induced G1 cell cycle arrest and cell migration, which has been demonstrated in renal carcinoma cells, human hepatocellular carcinoma cells, and breast cancer cells[11]. Besides, phospho-STAT3 (Tyr705) immunostaining is correlated with down-regulation of EAF2 in human prostate cancer specimens[15]. EAF2 knockout induces STAT3 phosphorylation (Tyr705) *in vivo* and *in vitro*, suggesting that EAF2 is a repressor of the STAT3 signaling pathway[15]. In our study, we found that overexpression of EAF2 decreased the levels of phosphorylated STAT3 (Tyr705) and TGF- $\beta$ 1 protein in CRC cells. In addition to this, we also found that silencing STAT3 reduced TGF- $\beta$ 1 protein expression. More than that, TGF- $\beta$ 1 recombinant protein eliminated the reduction of phosphorylated STAT3 (Tyr705) induced by EAF2 overexpression. Together, these results indicate that EAF2 overexpression may inhibit the activity of STAT3/TGF- $\beta$ 1 crosstalk pathway in CRC cells.


We found that EAF2 overexpression restrains the invasion and metastasis of CRC cells. It makes sense to further explore the role of EAF2 in regulating the activity of the STAT3/TGF- $\beta$ 1 crosstalk pathway in CRC cell invasion and metastasis. The results revealed that the invasiveness and metastasis capability of CRC cells weakened by EAF2 overexpression could be partially reversed by TGF- $\beta$ 1



**Figure 7 Overexpression of ELL-associated factor 2 in RKO cells inhibits tumor-induced angiogenesis.** A: Conditioned medium from RKO cells transfected with ELL-associated factor 2-overexpressed plasmids or empty control plasmids was collected to perform tube formation assay; B: Migration ability of human umbilical vein endothelial cells (HUVECs) analyzed by transwell migration assay; C: Migration ability of HUVECs analyzed by wound healing assay. And the results were measured with ImageJ software. The data are shown as the mean ± SD. \**P* < 0.001. HUVECs: Human Umbilical Vein Endothelial Cells; RKO-C: The group of Human Umbilical Vein Endothelial Cells cultured with conditioned medium from RKO cells cultured with 10% serum for 24 h; EAF2-OV: The group of human umbilical vein endothelial cells cultured with conditioned medium from RKO cells transfected with ELL-associated factor 2-overexpressed plasmids for 24 h; EAF2-NC: The group of human umbilical vein endothelial cells cultured with conditioned medium from RKO cells transfected with empty control plasmids for 24 h.

protein. Therefore, it was concluded that EAF2 overexpression inhibited the invasion and migration of CRC cells by down-regulating the activity of the STAT3/TGF-β1 crosstalk pathway. It is possible that therapeutic drugs targeting the STAT3/TGF-β1 signaling pathway may be effective for CRC subsets with down-regulated EAF2, elevated STAT3 phosphorylation, and up-regulated TGF-β1.


Tumor angiogenesis is critical not only for tumor growth, but also for tumor progression and metastasis[32]. Tumor angiogenesis is regulated by multiple angiogenic factors and angiogenic inhibitors[21]. The activation of the STAT3 pathway contributes to angiogenesis by increasing the expression of angiogenic factors, such as VEGFA, interleukin (IL)-8, HIF-1α, or IL-6[33]. The non-specific angiogenic factor TGF-β1 plays a proangiogenic role in CRC angiogenesis[34]. TGF-β1 signaling inactivation caused by dnTGFBR1 in tumor cells can reduce microvessel density and lumen sizes, and decrease tumor growth[35]. In keloid tissues, sumoylation of HIF-1α may increase the stability and an amplified effect on TGF-β/SMAD signaling[23]. Matrigel plug angiogenesis assay showed that EAF2 knockout mice responded to VEGF with significantly enhanced neovascularization[19]. And EAF2 is a



**Figure 8** Overexpression of ELL-associated factor 2 inhibited tumor-induced angiogenesis in RKO cells *via* the signal transducer and activator of transcription 3/transforming growth factor beta 1 pathway. **A:** Conditioned medium from RKO cells transfected with ELL-associated factor 2-overexpressed plasmids or treated with transforming growth factor beta 1 recombinant protein was collected to perform tube formation assay; **B:** Migration ability of human umbilical vein endothelial cells (HUVECs) analyzed by transwell migration assay; **C:** Migration ability of HUVECs analyzed by wound healing assay. And the results were measured with ImageJ software. The data are shown as the mean  $\pm$  SD. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.001$ . RKO-C: The group of human umbilical vein endothelial cells cultured with conditioned medium from RKO cells cultured with 10% serum for 24 h; EAF2-OV: The group of human umbilical vein endothelial cells cultured with conditioned medium from RKO cells transfected with ELL-associated factor 2-overexpressed plasmids for 24 h; RKO + T: The group of human umbilical vein endothelial cells cultured with conditioned medium from RKO cells treated with 5 ng/mL transforming growth factor- $\beta$ 1 pathway recombinant protein for 24 h; EAF2-OV + T: The group of human umbilical vein endothelial cells cultured with conditioned medium from RKO cells which were transfected with EAF-OV plasmid for 24 h and then cultured with 5 ng/mL transforming growth factor beta 1 pathway recombinant protein for 24 h.

negative regulator of HIF-1 $\alpha$  activity[20]. EAF2 binds to and stabilizes von Hippel-Lindau protein and then disrupts the HIF-1 $\alpha$ -mediated hypoxia signaling pathway[19,36]. Abnormal vasculogenesis occurred in EAF2 knockout mice[19]. We hypothesized that EAF2 may regulate CRC angiogenesis through the STAT3/TGF- $\beta$ 1 pathway. HUVECs were used in this study for evaluating the impact of RKO cells on angiogenesis. Besides, endothelial progenitor cells are also a good endothelial model for studying tumor-induced angiogenesis[37].

In this study, our results show that EAF2-overexpressing CRC cells can inhibit tube formation and migration of HUVECs. Besides, the inhibition of EAF2 overexpression on tube formation and migration of HUVECs may be reversed by TGF- $\beta$ 1 recombinant protein. This suggests that EAF2 overexpression inhibited CRC angiogenesis by suppressing the activity of the STAT3/TGF- $\beta$ 1 crosstalk pathway. However, this study still has some limitations, and lacks further studies on vascular regulatory factors released by vascular endothelial cells and changes in tumor microenvironment mediated by EAF2 and its downstream STAT3/TGF- $\beta$ 1 crosstalk pathway.



DOI: 10.4251/wjgo.v14.i10.1949 Copyright ©The Author(s) 2022.

**Figure 9 Schematic depiction of ELL-associated factor 2 regulating the signal transducer and activator of transcription 3/transforming growth factor beta 1 crosstalk pathway in this study.** EAF2: ELL-associated factor 2; p-STAT3: Phosphorylated-signal transducer and activator of transcription 3; TGF- $\beta$ 1: Transforming growth factor beta 1; CRC: Colorectal cancer; HUVECs: Human umbilical vein endothelial cells.

## CONCLUSION

In conclusion, our findings suggest that EAF2 protein is under-expressed in cancer tissue of patients with advanced CRC. And Kaplan-Meier survival analysis showed that the survival rate of the group with high EAF2 levels was higher than that of the group with low EAF2 levels. Moreover, as a tumor suppressor, EAF2 may play a tumor suppressive and protective role in the development of CRC by inhibiting the invasion, metastasis, and angiogenesis of CRC cells. The regulatory effect of EAF2 on the biological functions of CRC cells may be realized by regulating the STAT3/TGF- $\beta$ 1 crosstalk pathway (Figure 9). Further research on methods and technologies to increase EAF2 in CRC will be one of the future research directions, and exploration of upstream factors such as related non-coding RNAs may provide new diagnostic markers and novel therapeutic targets for CRC.

## ARTICLE HIGHLIGHTS

### Research background

There are few studies on the expression and role of ELL-associated factor 2 (EAF2) protein in colorectal cancer (CRC). The molecular mechanism of involvement of EAF2 in CRC invasion and metastasis remains unclear.

### Research motivation

EAF2 may play a tumor suppressive and protective role in the development of CRC by inhibiting the invasion, metastasis, and angiogenesis of CRC cells.

### Research objectives

We assessed the expression and localization of EAF2 protein in CRC specimens. Meanwhile, we cultured CRC cells *in vitro* to determine the expression of EAF2 protein and further investigate its effects on the biological function of CRC cells.

### Research methods

We used immunohistochemistry and western blot assay to detect the expression of EAF2 protein in CRC tissues from 70 patients. In addition, we applied plasmid transfection technology to study the effects of EAF2 on the invasion, migration, and angiogenesis of CRC cells *in vitro*.

### Research results

EAF2 protein was lowly expressed in cancer tissues of patients with advanced CRC. Kaplan-Meier survival analysis showed that the survival rate of the group with high EAF2 level was higher than that of the group with low EAF2 level. In addition, EAF2 affected the biological functions of CRC cells by regulating the STAT3/TGF- $\beta$ 1 crosstalk pathway.

**Research conclusions**

As a tumor suppressor, EAF2 may play a tumor suppressive and protective role in the development of CRC by inhibiting the invasion, metastasis, and angiogenesis of CRC cells *via* regulating the signal transducer and activator of transcription 3/transforming growth factor beta 1 crosstalk pathway. These findings may provide new diagnostic markers and novel therapeutic targets for CRC.

**Research perspectives**

Our data is beneficial to elucidate the molecular mechanism of CRC invasion and metastasis as well as explore new potential molecular markers and the direction of targeted therapy.

**FOOTNOTES**

**Author contributions:** Feng ML and Wu C designed the research study; Zhang HJ and Jiao TW performed the research; Zhou H and Liu MY contributed new reagents and analytic tools; Feng ML and Sun MJ analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.

**Supported by** the Natural Science Foundation of Liaoning Province, No. 2019-BS-279.

**Institutional review board statement:** This study was approved by the Institutional Review Board of The First Affiliated Hospital of China Medical University (Registration No. 2021-68-2).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Ming-Liang Feng 0000-0001-6624-9624; Can Wu 0000-0002-9532-8767; Hui-Jing Zhang 0000-0002-6322-2335; Huan Zhou 0000-0002-6299-2514; Tai-Wei Jiao 0000-0002-7679-6354; Meng-Yuan Liu 0000-0002-5058-1558; Ming-Jun Sun 0000-0003-0072-2575.

**S-Editor:** Wang JJ

**L-Editor:** Wang TQ

**P-Editor:** Wang JJ

**REFERENCES**

- 1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]
- 2 **Zacharakis M**, Xynos ID, Lazaris A, Smaro T, Kosmas C, Dokou A, Felekouras E, Antoniou E, Polyzos A, Sarantonis J, Syrios J, Zografos G, Papalambros A, Tsavaris N. Predictors of survival in stage IV metastatic colorectal cancer. *Anticancer Res* 2010; **30**: 653-660 [PMID: 20332485]
- 3 **McQuade RM**, Stojanovska V, Bornstein JC, Nurgali K. Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches. *Curr Med Chem* 2017; **24**: 1537-1557 [PMID: 28079003 DOI: 10.2174/0929867324666170111152436]
- 4 **Xiao W**, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. *Cancer Res* 2003; **63**: 4698-4704 [PMID: 12907652]
- 5 **Ai J**, Pascal LE, O'Malley KJ, Dar JA, Isharwal S, Qiao Z, Ren B, Rigatti LH, Dhir R, Xiao W, Nelson JB, Wang Z. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. *Oncogene* 2014; **33**: 2286-2294 [PMID: 23708662 DOI: 10.1038/onc.2013.190]
- 6 **Xiao W**, Zhang Q, Habermacher G, Yang X, Zhang AY, Cai X, Hahn J, Liu J, Pins M, Doglio L, Dhir R, Gingrich J, Wang Z. U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. *Oncogene* 2008; **27**: 1536-1544 [PMID: 17873910 DOI: 10.1038/sj.onc.1210786]
- 7 **Guo W**, Keener AL, Jing Y, Cai L, Ai J, Zhang J, Fisher AL, Fu G, Wang Z. FOXA1 modulates EAF2 regulation of AR

- transcriptional activity, cell proliferation, and migration in prostate cancer cells. *Prostate* 2015; **75**: 976-987 [PMID: 25808853 DOI: 10.1002/pros.22982]
- 8 **Zang Y**, Dong Y, Yang D, Xue B, Li F, Gu P, Zhao H, Wang S, Zhou S, Ying R, Wang Z, Shan Y. Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer. *Int Urol Nephrol* 2016; **48**: 695-700 [PMID: 26895851 DOI: 10.1007/s11255-015-1210-y]
  - 9 **Jo YS**, Kim SS, Kim MS, Yoo NJ, Lee SH. Candidate Tumor Suppressor Gene EAF2 is Mutated in Colorectal and Gastric Cancers. *Pathol Oncol Res* 2019; **25**: 823-824 [PMID: 30088132 DOI: 10.1007/s12253-018-0461-1]
  - 10 **Savas S**, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, Henderson MC, Choi YH, Briollais L, Ozelcik H, Tuzmen S. NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. *PLoS One* 2011; **6**: e18306 [PMID: 21483694 DOI: 10.1371/journal.pone.0018306]
  - 11 **Liu X**, Chen Z, Ouyang G, Song T, Liang H, Liu W, Xiao W. ELL Protein-associated Factor 2 (EAF2) Inhibits Transforming Growth Factor β Signaling through a Direct Interaction with Smad3. *J Biol Chem* 2015; **290**: 25933-25945 [PMID: 26370086 DOI: 10.1074/jbc.M115.663542]
  - 12 **Villalba M**, Evans SR, Vidal-Vanaclocha F, Calvo A. Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy. *Cell Tissue Res* 2017; **370**: 29-39 [PMID: 28560691 DOI: 10.1007/s00441-017-2633-9]
  - 13 **Liu RY**, Zeng Y, Lei Z, Wang L, Yang H, Liu Z, Zhao J, Zhang HT. JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells. *Int J Oncol* 2014; **44**: 1643-1651 [PMID: 24573038 DOI: 10.3892/ijo.2014.2310]
  - 14 **Wang B**, Liu T, Wu JC, Luo SZ, Chen R, Lu LG, Xu MY. STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration. *Biomed Pharmacother* 2018; **98**: 214-221 [PMID: 29268242 DOI: 10.1016/j.biopha.2017.12.035]
  - 15 **Pascal LE**, Wang Y, Zhong M, Wang D, Chakka AB, Yang Z, Li F, Song Q, Rigatti LH, Chaparala S, Chandran U, Parwani AV, Wang Z. EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. *Neoplasia* 2018; **20**: 351-363 [PMID: 29518696 DOI: 10.1016/j.neo.2018.01.011]
  - 16 **Jain RK**. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science* 2005; **307**: 58-62 [PMID: 15637262 DOI: 10.1126/science.1104819]
  - 17 **Ferrara N**. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* 2004; **25**: 581-611 [PMID: 15294883 DOI: 10.1210/er.2003-0027]
  - 18 **Folkman J**. Role of angiogenesis in tumor growth and metastasis. *Semin Oncol* 2002; **29**: 15-18 [PMID: 12516034 DOI: 10.1053/sonc.2002.37263]
  - 19 **Xiao W**, Ai J, Habermacher G, Volpert O, Yang X, Zhang AY, Hahn J, Cai X, Wang Z. U19/Eaf2 binds to and stabilizes von hippel-lindau protein. *Cancer Res* 2009; **69**: 2599-2606 [PMID: 19258512 DOI: 10.1158/0008-5472.CAN-08-2595]
  - 20 **Pang B**, Zheng XR, Tian JX, Gao TH, Gu GY, Zhang R, Fu YB, Pang Q, Li XG, Liu Q. EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling. *Oncotarget* 2016; **7**: 45134-45143 [PMID: 27259264 DOI: 10.18632/oncotarget.9761]
  - 21 **Liu JF**, Deng WW, Chen L, Li YC, Wu L, Ma SR, Zhang WF, Bu LL, Sun ZJ. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. *Mol Carcinog* 2018; **57**: 429-439 [PMID: 29215754 DOI: 10.1002/mc.22767]
  - 22 **Zhang ZH**, Li MY, Wang Z, Zuo HX, Wang JY, Xing Y, Jin C, Xu G, Piao L, Piao H, Ma J, Jin X. Convallatoxin promotes apoptosis and inhibits proliferation and angiogenesis through crosstalk between JAK2/STAT3 (T705) and mTOR/STAT3 (S727) signaling pathways in colorectal cancer. *Phytomedicine* 2020; **68**: 153172 [PMID: 32004989 DOI: 10.1016/j.phymed.2020.153172]
  - 23 **Lin X**, Wang Y, Jiang Y, Xu M, Pang Q, Sun J, Yu Y, Shen Z, Lei R, Xu J. Sumoylation enhances the activity of the TGF-β/SMAD and HIF-1 signaling pathways in keloids. *Life Sci* 2020; **255**: 117859 [PMID: 32474020 DOI: 10.1016/j.lfs.2020.117859]
  - 24 **Zonneville J**, Safina A, Truskinovsky AM, Arteaga CL, Bakin AV. TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. *BMC Cancer* 2018; **18**: 670 [PMID: 29921235 DOI: 10.1186/s12885-018-4587-z]
  - 25 **Beldi G**, Bahiraii S, Lezin C, Nouri Barkestani M, Abdelgawad ME, Uzan G, Naserian S. TNFR2 Is a Crucial Hub Controlling Mesenchymal Stem Cell Biological and Functional Properties. *Front Cell Dev Biol* 2020; **8**: 596831 [PMID: 33344453 DOI: 10.3389/fcell.2020.596831]
  - 26 **Liu JX**, Zhang D, Xie X, Ouyang G, Liu X, Sun Y, Xiao W. Eaf1 and Eaf2 negatively regulate canonical Wnt/β-catenin signaling. *Development* 2013; **140**: 1067-1078 [PMID: 23364330 DOI: 10.1242/dev.086157]
  - 27 **Simone F**, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. *Blood* 2003; **101**: 2355-2362 [PMID: 12446457 DOI: 10.1182/blood-2002-06-1664]
  - 28 **An Y**, Zhang S, Zhang J, Yin Q, Han H, Wu F, Zhang X. Overexpression of lncRNA NLIPMT Inhibits Colorectal Cancer Cell Migration and Invasion by Downregulating TGF-β1. *Cancer Manag Res* 2020; **12**: 6045-6052 [PMID: 32765103 DOI: 10.2147/CMAR.S247764]
  - 29 **Morikawa T**, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, Ogino S. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. *Clin Cancer Res* 2011; **17**: 1452-1462 [PMID: 21310826 DOI: 10.1158/1078-0432.CCR-10-2694]
  - 30 **Rokavec M**, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitala S, Slotta-Huspenina J, Bader FG, Greten FR, Hermeking H. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. *J Clin Invest* 2014; **124**: 1853-1867 [PMID: 24642471 DOI: 10.1172/JCI73531]
  - 31 **Zhang X**, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT, Turkson J. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. *Proc Natl Acad Sci U S A* 2012; **109**: 9623-9628 [PMID: 22623533 DOI: 10.1073/pnas.1121606109]
  - 32 **Naumov GN**, Aklsen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic

- switch. *Cell Cycle* 2006; **5**: 1779-1787 [PMID: 16931911 DOI: 10.4161/cc.5.16.3018]
- 33 **Sun W.** Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. *J Hematol Oncol* 2012; **5**: 63 [PMID: 23057939 DOI: 10.1186/1756-8722-5-63]
- 34 **Yang L,** Liu Z, Wen T. Multiplex fluorescent immunohistochemistry quantitatively analyses microvascular density (MVD) and the roles of TGF- $\beta$  signalling in orchestrating angiogenesis in colorectal cancer. *Transl Cancer Res* 2019; **8**: 429-438 [PMID: 35116775 DOI: 10.21037/tcr.2019.02.09]
- 35 **Du YE,** Tu G, Yang G, Li G, Yang D, Lang L, Xi L, Sun K, Chen Y, Shu K, Liao H, Liu M, Hou Y. MiR-205/YAP1 in Activated Fibroblasts of Breast Tumor Promotes VEGF-independent Angiogenesis through STAT3 Signaling. *Theranostics* 2017; **7**: 3972-3988 [PMID: 29109792 DOI: 10.7150/thno.18990]
- 36 **Pascal LE,** Ai J, Rigatti LH, Lipton AK, Xiao W, Gnarra JR, Wang Z. EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate. *Angiogenesis* 2011; **14**: 331-343 [PMID: 21638067 DOI: 10.1007/s10456-011-9217-1]
- 37 **Abdelgawad ME,** Desterke C, Uzan G, Naserian S. Single-cell transcriptomic profiling and characterization of endothelial progenitor cells: new approach for finding novel markers. *Stem Cell Res Ther* 2021; **12**: 145 [PMID: 33627177 DOI: 10.1186/s13287-021-02185-0]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

